New Approaches to Challenge Old Assumptions-B-Cell Depletion in Multiple Sclerosis

Affiliations

¹ Division of Neuroimmunology and Glial Biology, Weill Neurosciences Center, University of California San Francisco, San Francisco.
² Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, New York.

Editorial

Lauren Oommen et al. JAMA Neurol. 2023.

. 2023 Aug 1;80(8):775-777.

doi: 10.1001/jamaneurol.2023.1079.

¹ Division of Neuroimmunology and Glial Biology, Weill Neurosciences Center, University of California San Francisco, San Francisco.
² Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, New York.

No abstract available

Comment on

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. Roos I, et al. JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625. JAMA Neurol. 2023. PMID: 37307006 Free PMC article.